Trial Profile
A Randomized Phase II Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Dexamethasone; Floxuridine; Fluorouracil; Folinic acid; Heparin; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 03 Apr 2024 Planned End Date changed from 1 Mar 2024 to 1 Mar 2025.
- 03 Apr 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Mar 2025.
- 03 Apr 2023 Planned End Date changed from 1 Mar 2023 to 1 Mar 2024.